Organon & Co. (OGN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 19.50 |
| Open | 20.00 |
| Bid | 19.71 x 800 |
| Ask | 19.69 x 800 |
| Day's Range | 19.41 - 20.30 |
| 52 Week Range | 10.84 - 24.08 |
| Volume | |
| Avg. Volume | 2,380,020 |
| Market Cap | 5.043B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | 4.81 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.12 (5.71%) |
| Ex-Dividend Date | May 10, 2024 |
| 1y Target Est | N/A |
- Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024
- Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
© 2024 Yahoo. All rights reserved.